학술논문
LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study
Document Type
Abstract
Author
Source
In Immuno-Oncology and Technology December 2023 20 Supplement
Subject
Language
ISSN
2590-0188